Acepodia a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms, announced today that it has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug

Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients with newly diagnosed Philadelphia chromosome

ARTBIO, Inc. a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), and 3B Pharmaceuticals GmbH (3BP), a private biotechnology company developing targeted radiopharmaceutical

Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and drug delivery,

Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely targeted, today announces it has established a UK subsidiary

Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, and Waterstone, a reliable partner for its worldwide customers through continuous improvement and innovation to ensure high quality and sustainable service

QIAGEN today announced a collaboration with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes.

Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a significant milestone for both Theragent and its sponsor client, CellVax Therapeutics Inc.

Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe Sjögren’s disease (SjD)

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated